___

• Serhan CN, Jain A, Marleau S et al. Reduced inflammation an tissue damage in transgenic rabbits overexpressing 15-lipoxyge-nase and endogenous anti- inflammatory lipid mediators. J Immunol 2003; 171: 6856-6865.
• Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003; 82: 82- 90.
• Perretti M, Chiang N, La M et al. Endegenous lipid- pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 2002; 8: 1296-1302. anti-inflammatory
• Gilroy DW, Lawrence T, Perretti M et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401- 416.
• Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders, Philadelphia, 2005.
• Serhan CN. Resolution phase of inflammation: novel proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137. and
• Preshaw PM, Taylor JJ. Periodontal Pathogenesis. In: Carranza’s Clinical Periodontology. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Elsevier Saunders, 11th ed., 205.
• Cotran RS, Kumar V, Collins T. Cellulapathology I. Cell injury and cell death. Saunders, Philadelphia, 1999, 1-29.
• Van Dyke TE. Control of inflammation and periodontitis. Periodontol 2000 2007; 45: 158-166.
• Kumar V, Abbas AK, Fausto N et al. Robbins Basic Pathology. 8th ed, Philadelphia, Saunders, 2007.
• Simopoulos AP, Leaf A, Salem N Jr. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J Am Coll Nur 1999; 18: 487-489.
• Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929; 82: 345.
• Lands WEM. Diets could prevent many diseases. Lipids 2003; 38: 317-321.
• Bazan NG. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Wurtman RJ, Wurtman JJ, editors. Nutrition and The Brain. New York, Raven Press, 199, 1-22.
• Salem N Jr, Litman B, Kim HY et al. Mechanism of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
• Kelley DS. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 2001; 17 (7-8): 669-673.
• Benito P. The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 2001; 36 (3): 221-227. 18. Murakami M. Regulatory phospholipase A2. Crit. Rev Immunol 1997; 17 (3- 4): 225-283. functions of
• Hamberg M., Samuelsson B. Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J Biol Chem 1966; 241 (2): 257-263. 20. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds endoperoxides. Proc Natl Acad Sci 1975; 72 (8): 2994-2998. from prostaglandin 21. Yoshikai Y. Roles of leukotrienes in acute inflammation caused by bacterial infection. Curr Opin Infect Dis 2001; 14 (3): 257-263. prostaglandins and
• Samuelsson B. An elucidation of the arachidonic acid thromboxane and leukotrienes. Drugs 33 1987; (Suppl. 1): 2-9. of progtaglandins,
• Higgs GA. Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins 1976; 12 (5):749-757.
• Vane JR. The mode of action of aspirin and similar compounds, J Allergy Clin Immunol 1976; 58 (6): 691-712. 25. Vane JR.
• Prostaglandins as mediators of
• inflammation. Adv Prostaglandin Thromboxane
• Res 1976; 2: 791-801.
• Banion MKO’, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid- regulated inflammatory cyclooxgenase. Proc Natl Acad Sci 1992; 89 (11): 4888-4892. 27. Banion M.K.O’.
• Cyclooxgenase-2:molecular
• biology, pharmacology, and neurobiology, Crit Rev
• Neurobiol 1999; 13 (1): 45-82.
• Banion MKO’, Olschowka JA. Localization and distribution of cyclooxgenase-2 inbrain tissue by immunohistochemistry. Methods Mol Biol 1999; 120: 55-66.
• Samuelsson B, The leukotrienes: an introduction. Adv Prostaglandin Thromboxane Leukot Res 1982; 9: 1-17.
• Serhan CN, Drazen JM. Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?. J Clin Invest 1997; 99 (6): 1147-1148. CD. 31. Funk
• Prostaglandins and leukotrienes:
• advances in eicosanid biology. Science 2001; 294 (5548): 1871-1875.
• Bandeira-Melo-C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002; 109 (3): 393-400.
• Diamond P, McGinty A, Sugrue D et al. Regulation of leukocyte trafficking by lipoxins. Clin Chem Lab Med 1999; 37: 293-297.
• Samuelsson B. Leukotrienes structures, biosynthesis, and biological effects. Science 1987; 237 (4819): 1171-1176. lipoxins:
• Serhan CN, Sheppard KA. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990; 85 (3): 772-780.
• Serhan CN, Fiore S, Levy BD. Cell-cell interactions characterization of lipoxin A4 receptors. Ann NY Acad Sci 1994; 744: 166-180. generation and
• Levy BD. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612-619.
• Brady HR, Serhan CN. Lipoxins: putative braking signals in host defense, inflammation and hypersensivity. Curr Opin Nephrol Hypertens 1996; 5 (1): 20-27.
• Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci 1984; 81 (17): 5335-5339.
• Badr KF. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells:evidence of competition ata common receptor. Proc Natl Acad Sci 1989; 86 (9): 3438-3442.
• Lee TH. Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure- function relationships. Biochem Biophys Res Commun 1991; 180 (3): 1416-1421.
• Serhan CN, Romano M. Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J Lipid Mediat Cell Signal 1995; 12 (2-3): 293-306.
• Brezinski ME, Serhan CN. Selective incorporation of phosphatidylinositol of human neutrophils: agonist- induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci 1990; 87 (16) : 6248-6252. acid in
• Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci 1995; 92 (21): 9475-9479. 45. Edenius C, Haeggstrom conversion JA. Transcellular arachidonic acid to lipoxins in mixed human platelet-granulocye suspensions. Biochem Biophys Res Commun 1988; 157: 801-807. endogenous
• Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulatig actor- primed neutrophils. J Exp Med 1990; 72: 1451- 1457.
• Romano M, Serhan CN. Lipoxin generation by permeabilized human platelets Biochemistry 1992; 31: 8269-8277.
• Sheppard KA, Greenberg SM, Funk CD et al. Lipoxin generation by human megakaryocyte- induced 12-lipoxygenase. Biochim Biophys Acta 1992; 1133: 223-234.
• Romano M, Chen XS, Takahashi Y et al. Lipoxin synthase lipoxygenase. Biochem J 1993; 296(Pt 1): 127-133. human platelet 12
• Lehr HA, Olofsson AM, Carew TE et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994; 71: 380-386.
• Mayadas TN, Mendrick DL, Brady HR et al. Acute passive nephritis in P-selectin-deficient mice. Kidney Int 1996; 49: 1342-1349. basement membrane
• Fiore S, Serhan CN. Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: stabilization of eicosanoids by liposomes. Biochem Biophys Res Commun 1989; 159:477-481.
• Krump E, Picard S, Mancini I et al. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in liga-and-activated human neutrophils. J Exp Med 1997; 186: 1401-1406.
• Edenius C, Kumlin M, Bjork et al. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett 1990; 272: 25-28.
• Garrick R, Wong PY. Enzymatic formation and regulatory function of lipoxins and leukotriene B4 in rat kidney mesangial cells. Adv Exp Med Biol 1991; 314: 361-369.
• Edenius C, Stenke L, Lindgren A. On the mechanism of transcellular lipoxin formation in human platelets and granulocytes. Eur J Biochem 1991; 199: 401-409.
• Tornhamre S, Gigou A, Edenius C et al. Conversion of 5,6-dihydroxyeicosatetraenoic acids. A novel pathway for lipoxin formation by human platelets. FEBS Lett 1992; 304: 78-82.
• Chavis C, Vachier I, Chanez P et al. 5(S), 15(S)- Dihyddroxyeicosatetraenoic generation in human polymorphonuclear cells dual specificity of lipoxygenase towards endogenous and exogenous precursors. J Exp Med 1996; 183: 1633-1643. acid and lipoxin
• Thomas E, Leroux JL, Blotman F. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm Res 1995; 44: 121-124.
• Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-140.
• Serhan CN, Maddox J, Petasis NA et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995; 34: 14609-14615.
• Levy GN. Prostaglandin H synthases, nonsteroidal antiinflammatory drugs and colon cancer. FASEB J 1997; 11: 234-247.
• Fierro IM, Kutok JL, Serhan CN. Novel lipd mediator regulators of endothelial cell proliferation and migration: aspirin-triggered -15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002; 300: 385-392.
• Kantarcı A and Van Dyke TE. Lipoxins in chronic ınflammation. Crit Rev Oral Biol Med 2003; 14: 4.
• Lee TH, Crea AE, Gant V et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4 , D4 and E4 in the bronchoalveolar lavage fluids obtaine from patients with selected pulmonary diseases. Am Rev Respir Dis 1990; 141: 1453-1458.
• Papayianni A, Serhan CN, Phillips M et al. Transcellular biosynthesis of lipoxin a4 during adhesion experimental immune complex glomerulonephritis. Kidney Int 1995; 47: 1295-1302. neutrophils in
• Chavis C, Vachier I, Godard P et al. Lipoxins and other arachidonate derived mediators in bronchial asthma. Thorax 2000; 55(Supple)2: 38-41.
• Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggersintracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 1992; 86: 56- 63.
• Stenke L, Reizenstein P, Lindgren JA. Leukotrienes and lipoxins-new potential performers in the regulation of human myelopoiesis. Leukemia Res 1994; 18: 727-732.
• Chiang N, Takano T, Clish CB et al. Aspirin triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther 1998; 287: 779-790.
• Sanak M, Levy BD, Clish CB et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin- intolerant asthmatics. Eur Respir J 2000; 16: 44-49.
• Stenke L, Edenius C, Samuelsson B et al. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2989-2995.
• Claria J, Titos E, Jimenez W et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 1998; 115: 147-156.
• Pouliot M, Clish CB, Petasis NA et al. Lipoxin A4 analogues Porphyromonas cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000; 39: 4761-4768. to for gingivalis:
• Dewhirst FE, Moss DE, Offenbacher S et al. Levels of prostaglandin E2, thromboxane, and prostacyclin in periodontal tissue. J Periodonal Res 1983; 18: 156-163.
• Romano M. Lipoxin and Aspirin-Triggered Lipoxins. The Sci World J 2010; 10: 1048-1064.
• Fierro IM, Colgan SP, Bernasconi G et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 2003; 170: 2688– 2694. in chemotaxis and
• Scalia R, Gefen J, Petasis NA et al. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc Natl Acad Sci 1997; 94: 9967–9972.
• Bandeira-Melo C, Bozza PT, Diaz BL et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi- LXA4 trafficking. J Immunol 2000; 164: 2267–2271.
• Jozsef L, Zouki C, Petasis NA et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci 2002; 99: 13266– 13271.
• Gewirtz AT, Fokin VV, Petasis NA et al. LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively degranulation. Am J Physiol 1999; 276: 988–994.
• Sodin-Semrl S, Taddeo B, Tseng D et al. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000; 164: 2660–2666.
• Hachicha M, Pouliot M, Petasis NA et al. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine- chemokine axis. J Exp Med 1999; 189: 1923–1930.
• Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345–4355.
• Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V et al. ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008; 153: 956–965.
• Baker N, O'Meara SJ, Scannell M et al. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009; 182: 3819– 3826.
• Leedom AJ, Sullivan AB, Dong B et al. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol 2010; 176: 74–84.
• Takano T, Clish CB, Gronert K et al. Neutrophil- mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin İnvest 1998; 101: 819-826.
• Maddox JF, Colgan SP, Clish CB et al. Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin-analogs with increased biologic activity. FASEB J 1998; 12: 487-494. Sorumlu Yazar:
• Meltem Karşıyaka Hendek
• Kırıkkale Üniversitesi, Dişhekimliği Fakültesi
• Periodontoloji Anabilim Dalı Kırıkkale/TÜRKİYE
• Tel: +90 318 224 49 27/ 3535
• Fax: +90 318 225 06 85
• e-mail: mltmkrsyk@yahoo.com